• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder.

作者信息

Leech Ashley A, McNeer Elizabeth, Roberts Andrew W, Dusetzina Stacie B, Lai Pikki, Morgan Jake R, Patrick Stephen W

机构信息

Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.

Vanderbilt Center for Child Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.

出版信息

JAMA Intern Med. 2023 Sep 1;183(9):1023-1026. doi: 10.1001/jamainternmed.2023.2826.

DOI:10.1001/jamainternmed.2023.2826
PMID:37548972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10407758/
Abstract
摘要

相似文献

1
Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder.丁丙诺啡自付费用与患有阿片类物质使用障碍的私人保险成年人停药情况
JAMA Intern Med. 2023 Sep 1;183(9):1023-1026. doi: 10.1001/jamainternmed.2023.2826.
2
Early Discontinuation of Buprenorphine Therapy for Opioid Use Disorder Among Privately Insured Adults.阿片类物质使用障碍患者中私人保险成年人丁丙诺啡治疗的早期停药。
Psychiatr Serv. 2020 Aug 1;71(8):779-788. doi: 10.1176/appi.ps.201900309. Epub 2020 Apr 8.
3
Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts.丁丙诺啡/纳洛酮治疗阿片类物质使用障碍患者停药模式：对马萨诸塞州商业保险人群的一项研究。
J Subst Abuse Treat. 2021 Dec;131:108416. doi: 10.1016/j.jsat.2021.108416. Epub 2021 Apr 20.
4
Out-of-Pocket Costs and Payer Types for Buprenorphine Among US Youth Aged 12 to 19 Years.美国12至19岁青少年丁丙诺啡的自付费用和支付方类型
JAMA Pediatr. 2023 Oct 1;177(10):1096-1098. doi: 10.1001/jamapediatrics.2023.2376.
5
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.在美国商业保险人群中，接受阿片类药物使用障碍治疗的个体中，可注射纳曲酮、口服纳曲酮和丁丙诺啡的使用和停药情况。
J Subst Abuse Treat. 2018 Feb;85:90-96. doi: 10.1016/j.jsat.2017.07.001. Epub 2017 Jul 3.
6
Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015.美沙酮使用与阿片类药物使用障碍治疗费用：2003 年至 2015 年趋势
Psychiatr Serv. 2018 Jul 1;69(7):832-835. doi: 10.1176/appi.ps.201700315. Epub 2018 May 8.
7
Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.丁丙诺啡/纳洛酮剂量对阿片类药物依赖成人治疗持续时间、资源利用和成本的影响分析：一项对美国公共和私人医疗保健索赔的回顾性研究
Postgrad Med. 2014 Sep;126(5):113-20. doi: 10.3810/pgm.2014.09.2805.
8
Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.在有私人保险的成年人中，丁丙诺啡治疗阿片类药物使用障碍的 3 年保留率。
Psychiatr Serv. 2018 Jul 1;69(7):768-776. doi: 10.1176/appi.ps.201700363. Epub 2018 Apr 16.
9
Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.重新思考阿片类药物剂量递减、处方阿片类药物依赖以及丁丙诺啡的适应症
Ann Intern Med. 2019 Sep 17;171(6):427-429. doi: 10.7326/M19-1488. Epub 2019 Aug 27.
10
Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients.缓释丁丙诺啡用于治疗医疗补助覆盖患者阿片类物质使用障碍的可及性
Psychiatr Serv. 2021 Feb 1;72(2):225-226. doi: 10.1176/appi.ps.202000165. Epub 2020 Sep 10.

引用本文的文献

1
Cost-Sharing and Buprenorphine Prescription Dispensing.费用分担与丁丙诺啡处方配药
JAMA Health Forum. 2025 Jul 3;6(7):e251913. doi: 10.1001/jamahealthforum.2025.1913.
2
Trends in Access to Medications for Opioid Use Disorder.阿片类物质使用障碍药物获取趋势。
JAMA Health Forum. 2025 Apr 4;6(4):e250393. doi: 10.1001/jamahealthforum.2025.0393.
3
Comparative effectiveness of buprenorphine adherence with telemedicine vs. in-person for rural and urban patients.丁丙诺啡通过远程医疗与面对面治疗对农村和城市患者的依从性比较效果。
J Am Pharm Assoc (2003). 2025 Mar-Apr;65(2):102318. doi: 10.1016/j.japh.2024.102318. Epub 2024 Dec 27.
4
Payment-related barriers to medications for opioid use disorder: A critical review of the literature and real-world application.支付相关的阿片类药物使用障碍治疗障碍：文献综述及真实世界应用的批判性评价。
J Subst Use Addict Treat. 2024 Oct;165:209441. doi: 10.1016/j.josat.2024.209441. Epub 2024 Jun 19.
5
Association Between Cost-Sharing and Buprenorphine Prescription Abandonment.费用分担与丁丙诺啡处方放弃的关联。
J Gen Intern Med. 2024 Sep;39(12):2160-2168. doi: 10.1007/s11606-024-08819-2. Epub 2024 Jun 18.
6
Use of in-network insurance benefits is critical for improving retention in telehealth-based buprenorphine treatment.使用网络内保险福利对于提高基于远程医疗的丁丙诺啡治疗的留存率至关重要。
Health Aff Sch. 2024 Jan 30;2(3):qxae009. doi: 10.1093/haschl/qxae009. eCollection 2024 Mar.
7
The limits of innovation: Directly addressing known challenges is necessary to improve the real-world experience of novel medications for opioid use disorder.创新的局限：直接应对已知挑战对于改善阿片类药物使用障碍新型药物的真实世界体验至关重要。
Acad Emerg Med. 2023 Dec;30(12):1285-1287. doi: 10.1111/acem.14814. Epub 2023 Oct 28.